Aethlon Medical annual ebitda
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Aethlon Medical EBITDA Growth & History (AEMD)
Aethlon Medical's calculated EBITDA was −$7.0M for fiscal 2026.
View full Aethlon Medical company overviewAethlon Medical annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$7.0M | $2.0M | — |
| 2025 | 2025-03-31 | −$9.0M | $3.3M | — |
| 2024 | 2024-03-31 | −$12.3M | −$619,765 | — |
| 2023 | 2023-03-31 | −$11.7M | −$1.4M | — |
| 2022 | 2022-03-31 | −$10.3M | −$2.4M | — |
| 2021 | 2021-03-31 | −$7.9M | −$1.9M | — |
| 2020 | 2020-03-31 | −$5.9M | $64,700 | — |
| 2019 | 2019-03-31 | −$6.0M | −$1.2M | — |
| 2018 | 2018-03-31 | −$4.8M | $1.3M | — |
| 2017 | 2017-03-31 | −$6.1M | −$1.7M | — |
| 2016 | 2016-03-31 | −$4.3M | −$390,809 | — |
| 2015 | 2015-03-31 | −$4.0M | −$920,660 | — |
| 2014 | 2014-03-31 | −$3.0M | $530,029 | — |
| 2013 | 2013-03-31 | −$3.6M | −$467,754 | — |
| 2012 | 2012-03-31 | −$3.1M | $1.4M | — |
| 2011 | 2011-03-31 | −$4.5M | — | — |
Aethlon Medical quarterly ebitda
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$1.5M | $203,411 | — |
| Q4 2026 | 2026-03-31 | −$1.8M | $70,029 | — |
| Q3 2026 | 2025-12-31 | −$2.0M | −$249,574 | — |
| Q2 2026 | 2025-09-30 | −$1.4M | $1.4M | — |
| Q1 2026 | 2025-06-30 | −$1.7M | $825,045 | — |
| Q4 2025 | 2025-03-31 | −$1.9M | $480,365 | — |
| Q3 2025 | 2024-12-31 | −$1.7M | $1.7M | — |
| Q2 2025 | 2024-09-30 | −$2.8M | $267,627 | — |
| Q1 2025 | 2024-06-30 | −$2.5M | $783,037 | — |
| Q4 2024 | 2024-03-31 | −$2.4M | −$2,189 | — |
| Q3 2024 | 2023-12-31 | −$3.5M | −$703,988 | — |
| Q2 2024 | 2023-09-30 | −$3.1M | $528,816 | — |
| Q1 2024 | 2023-06-30 | −$3.3M | −$442,404 | — |
| Q4 2023 | 2023-03-31 | −$2.4M | $1.4M | — |
| Q3 2023 | 2022-12-31 | −$2.8M | −$261,354 | — |
| Q2 2023 | 2022-09-30 | −$3.6M | −$1.7M | — |
| Q1 2023 | 2022-06-30 | −$2.9M | −$788,659 | — |
| Q4 2022 | 2022-03-31 | −$3.8M | −$1.5M | — |
| Q3 2022 | 2021-12-31 | −$2.5M | −$76,617 | — |
| Q2 2022 | 2021-09-30 | −$1.9M | −$177,662 | — |
| Q1 2022 | 2021-06-30 | −$2.1M | −$685,124 | — |
| Q4 2021 | 2021-03-31 | −$2.3M | −$479,320 | — |
| Q3 2021 | 2020-12-31 | −$2.4M | −$1.6M | — |
| Q2 2021 | 2020-09-30 | −$1.8M | −$62,799 | — |
| Q1 2021 | 2020-06-30 | −$1.4M | $161,672 | — |
| Q4 2020 | 2020-03-31 | −$1.8M | −$189,839 | — |
| Q3 2020 | 2019-12-31 | −$866,165 | $1.1M | — |
| Q2 2020 | 2019-09-30 | −$1.7M | −$360,296 | — |
| Q1 2020 | 2019-06-30 | −$1.6M | −$474,157 | — |
| Q4 2019 | 2019-03-31 | −$1.6M | −$322,168 | — |
| Q3 2019 | 2018-12-31 | −$2.0M | −$800,281 | — |
| Q2 2019 | 2018-09-30 | −$1.3M | −$112,175 | — |
| Q1 2019 | 2018-06-30 | −$1.1M | $61,760 | — |
| Q4 2018 | 2018-03-31 | −$1.3M | $235,622 | — |
| Q3 2018 | 2017-12-31 | −$1.2M | $74,917 | — |
| Q2 2018 | 2017-09-30 | −$1.2M | $989,436 | — |
| Q1 2018 | 2017-06-30 | −$1.2M | −$29,489 | — |
| Q4 2017 | 2017-03-31 | −$1.5M | −$421,998 | — |
| Q3 2017 | 2016-12-31 | −$1.2M | −$155,574 | — |
| Q2 2017 | 2016-09-30 | −$2.2M | −$1.1M | — |
| Q1 2017 | 2016-06-30 | −$1.1M | −$40,801 | — |
| Q4 2016 | 2016-03-31 | −$1.1M | $46,900 | — |
| Q3 2016 | 2015-12-31 | −$1.1M | $3,423 | — |
| Q2 2016 | 2015-09-30 | −$1.1M | −$523,169 | — |
| Q1 2016 | 2015-06-30 | −$1.1M | $82,037 | — |
| Q4 2015 | 2015-03-31 | −$1.1M | −$320,271 | — |
| Q3 2015 | 2014-12-31 | −$1.1M | $145,268 | — |
| Q2 2015 | 2014-09-30 | −$591,854 | −$364,349 | — |
| Q1 2015 | 2014-06-30 | −$1.2M | −$381,308 | — |
| Q4 2014 | 2014-03-31 | −$803,064 | $42,344 | — |
| Q3 2014 | 2013-12-31 | −$1.2M | −$288,579 | — |
| Q2 2014 | 2013-09-30 | −$227,505 | $569,572 | — |
| Q1 2014 | 2013-06-30 | −$781,362 | $206,692 | — |
| Q4 2013 | 2013-03-31 | −$845,408 | $8,801 | — |
| Q3 2013 | 2012-12-31 | −$934,331 | −$597,088 | — |
| Q2 2013 | 2012-09-30 | −$797,077 | $80,921 | — |
| Q1 2013 | 2012-06-30 | −$988,054 | $39,612 | — |
| Q4 2012 | 2012-03-31 | −$854,209 | $79,419 | — |
| Q3 2012 | 2011-12-31 | −$337,243 | $704,540 | — |
| Q2 2012 | 2011-09-30 | −$877,998 | $526,972 | — |
| Q1 2012 | 2011-06-30 | −$1.0M | $129,967 | — |
| Q4 2011 | 2011-03-31 | −$933,628 | — | — |
| Q3 2011 | 2010-12-31 | −$1.0M | — | — |
| Q2 2011 | 2010-09-30 | −$1.4M | — | — |
| Q1 2011 | 2010-06-30 | −$1.2M | — | — |
Aethlon Medical ebitda trends
Over the last five fiscal years, Aethlon Medical's ebitda increased from −$7.9M to −$7.0M, a change of $881,582. The latest reported quarter, Q1 2027, shows −$1.5M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aethlon Medical source filings ↗Community posts
Aethlon agrees to North Immunology merger backed by $180 million financing
Aethlon ($AEMD) Medical agreed to an all-stock merger with North Immunology, accompanied by a private placement described as approximately $180 million in gross proceeds. That amount includes the conversion of roughly $34 million of existin ...
